NATCO lists 29 US Para IV filings and 20+ FTF opportunities

NATCO Pharma Limited reported 29 Para IV filings in its US pipeline and more than 20 first-to-file opportunities, including sole and shared positions, as of 30 September 2026. NATCO’s disclosed key sole first-to-file list names eight products, including semaglutide medicines Ozempic and Wegovy and six cancer-focused brands.

What does NATCO’s US pipeline contain?

NATCO’s disclosed US pipeline contains 29 Para IV filings and more than 20 first-to-file opportunities, a total that includes both sole and shared first-to-file positions. The presentation separates eight key sole FTFs, with FTF meaning first-to-file, from nine other key Para IV products in a category labelled “Filing on NCE-1 date.”

The 17 entries named across the two lists are not necessarily 17 separate molecules or commercial opportunities. Kyprolis, containing carfilzomib, appears in both lists, with a 10 mg presentation among the sole FTFs and a 60 mg/ml presentation in the NCE-1-date list. Ozempic, containing semaglutide, also appears in both lists, while Wegovy is separately listed for semaglutide across all strengths.

Which products are NATCO’s sole first-to-file opportunities?

NATCO identifies eight key sole FTF Para IV products: Kyprolis, Imbruvica, Zydelig, Lynparza, Ozempic, Balversa, Wegovy and Tabrecta. Six of the eight are listed for cancer-related indications, including multiple myeloma, leukemia, blood and bone marrow cancer, ovarian or breast cancer, bladder cancer and lung cancer.

The two non-cancer sole FTF entries are both linked to semaglutide but are listed for different indications and presentations. Ozempic is identified for diabetes at two pen strengths, 8 mg/3 ml and 2 mg/3 ml, whereas Wegovy is identified for weight loss across all strengths. The presentation does not provide expected launch dates, patent-expiry dates or sales estimates for either product.

Which other Para IV products does NATCO list?

NATCO lists nine key Para IV products under its “Filing on NCE-1 date” category: Eliquis, Ozempic, Lonsurf, Yondelis, Calquence, Kyprolis, Nurtec, Jevtana and Evrysdi. The list covers anticoagulation, diabetes, five cancer-related uses, migraine and spinal muscular atrophy.

Eliquis contains apixaban and is classified as an anticoagulant, while the Ozempic entry refers to a semaglutide pen in two strengths for diabetes. Nurtec, containing rimegepant, is listed for migraine, and Evrysdi oral solution, containing risdiplam, is listed for spinal muscular atrophy. These four entries extend the named list beyond oncology and metabolic medicines.

The remaining five entries are tied to oncology: Lonsurf for metastatic colorectal cancer, Yondelis for advanced soft-tissue sarcoma or ovarian cancer, Calquence for blood cancer, Kyprolis for multiple myeloma, and Jevtana for cancer. NATCO lists Kyprolis as carfilzomib 60 mg/ml in this category, compared with the 10 mg carfilzomib sole-FTF entry, distinguishing presentations within the same brand.

How is NATCO’s pipeline spread across therapeutic areas?

NATCO’s named pipeline is weighted toward cancer medicines, with six of eight sole FTF entries and five of nine NCE-1-date entries carrying cancer-related indications. Across the two disclosed lists, the oncology brands include Kyprolis, Imbruvica, Zydelig, Lynparza, Balversa, Tabrecta, Lonsurf, Yondelis, Calquence and Jevtana, although Kyprolis is repeated.

Semaglutide is the other prominent molecule, appearing in three listed entries: Ozempic among the eight sole FTFs, Wegovy among the same eight, and Ozempic again among the nine NCE-1-date products. The source identifies diabetes for Ozempic and weight loss for Wegovy, but it does not quantify the number of distinct semaglutide filings within the overall count of 29.

The disclosed indications also include an anticoagulant, migraine therapy and spinal muscular atrophy. That range is visible in the nine-product NCE-1-date list through Eliquis, Nurtec and Evrysdi. NATCO provides a pipeline count and selected product lists rather than a breakdown of all 29 Para IV filings by therapy area, filing status or expected timing.

How did NATCO’s Q2FY27 segments change alongside the pipeline disclosure?

NATCO’s Q2FY27 consolidated revenue was Rs 1,019.4 crore, down from Rs 1,463 crore in Q2FY26 but up from Rs 794.4 crore in Q1FY27. International formulations, including profit share and subsidiaries, were Rs 668.4 crore in Q2FY27, compared with Rs 1,140.2 crore a year earlier and Rs 477.1 crore in the preceding quarter. The presentation does not attribute these revenue movements to the 29-filed US pipeline.

Domestic formulations rose to Rs 145.7 crore in Q2FY27 from Rs 105.4 crore in Q2FY26 and Rs 136.4 crore in Q1FY27, while total pharmaceutical formulations declined year on year but rose sequentially. Earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 310 crore, versus Rs 679.2 crore in Q2FY26 and Rs 245.7 crore in Q1FY27; the EBITDA margin was 30.4%, compared with 46.4% and 30.9%, respectively.

Conclusion

NATCO’s September 2026 US pipeline disclosure shows 29 Para IV filings and more than 20 first-to-file opportunities, with named products concentrated in oncology and repeated semaglutide exposure through Ozempic and Wegovy. The lists establish the product and indication mix, but do not disclose filing outcomes, launch timing or the commercial contribution of individual products.

The presentation schedules NATCO’s Q2FY27 earnings call for 13 November 2026 at 4.00 PM Indian Standard Time to discuss operational and financial performance. The source does not state whether management will provide additional detail on the more than 20 first-to-file opportunities, the 29-filing count or specific semaglutide and carfilzomib entries.